Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.
Nouscom has raised $7.6M in total funding. The most recent round was Series C. The last funding was announced in March 2024.
Nouscom's investors include Bpifrance, Versant Ventures, 5AM Ventures, Panakes Partners, EQT Life Sciences.
Nouscom is headquartered in Basel, Switzerland.
Nouscom is a biotech company that develops a series of immunotherapies that are capable of selectively killing tumor cells.
Nouscom is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nouscom — Funding & Investors." VCBacked, March 21, 2024, https://www.vcbacked.co/company/nouscom. Accessed September 14, 2026.
VCBacked. (2024). Nouscom — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/nouscom
{{cite web |title=Nouscom — Funding & Investors |url=https://www.vcbacked.co/company/nouscom |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated